Literature DB >> 30760861

Accumulation of fructose 1,6-bisphosphate protects clear cell renal cell carcinoma from oxidative stress.

Jun Wang1, Qi Wu1,2, Jianxin Qiu3.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is characterized by the activation of hypoxia-inducible factors and enhanced aerobic glycolysis. In our previous study, metabolic profiling revealed a threefold increase of fructose 1,6-bisphosphate (FBP) in ccRCC tissue compared with normal kidney tissue. As an important intermediate metabolite, its role in cancer development remains unknown. We found that high levels of FBP were required for cancer growth because of its ability to affect the redox status. Mechanistically, FBP regulated the redox status partially by suppressing NADPH oxidase isoform NOX4 activity in ccRCC cells. ccRCC maintained high levels of FBP through the downregulation of aldolase B (ALDOB). Reduction of FBP levels in cancer cells by the ectopic expression of ALDOB disrupted redox homeostasis, arrested cancer proliferation, and sensitized ccRCC cells to a chemotherapy agent (paclitaxel). Furthermore, low expression of ALDOB portended significantly worse disease-free survival and overall survival in ccRCC patients. In summary, the downregulation of ALDOB and accumulation of FBP promote ccRCC growth by counteracting oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30760861     DOI: 10.1038/s41374-019-0203-3

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial.

Authors:  Jen-Tsan Chi; Pao-Hwa Lin; Vladimir Tolstikov; Lauren Howard; Emily Y Chen; Valerie Bussberg; Bennett Greenwood; Niven R Narain; Michael A Kiebish; Stephen J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-25       Impact factor: 5.455

2.  Differential Expression of ADP/ATP Carriers as a Biomarker of Metabolic Remodeling and Survival in Kidney Cancers.

Authors:  Lucia Trisolini; Luna Laera; Maria Favia; Antonella Muscella; Alessandra Castegna; Vito Pesce; Lorenzo Guerra; Anna De Grassi; Mariateresa Volpicella; Ciro Leonardo Pierri
Journal:  Biomolecules       Date:  2020-12-30

3.  Identification of Hub Genes Associated With Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis.

Authors:  Hao Huang; Ling Zhu; Chao Huang; Yi Dong; Liangliang Fan; Lijian Tao; Zhangzhe Peng; Rong Xiang
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

4.  Single-cell transcriptomics reveals common epithelial response patterns in human acute kidney injury.

Authors:  Kai-Uwe Eckardt; Philipp Enghard; Nikolaus Rajewsky; Kai M Schmidt-Ott; Christian Hinze; Christine Kocks; Janna Leiz; Nikos Karaiskos; Anastasiya Boltengagen; Shuang Cao; Christopher Mark Skopnik; Jan Klocke; Jan-Hendrik Hardenberg; Helena Stockmann; Inka Gotthardt; Benedikt Obermayer; Laleh Haghverdi; Emanuel Wyler; Markus Landthaler; Sebastian Bachmann; Andreas C Hocke; Victor Corman; Jonas Busch; Wolfgang Schneider; Nina Himmerkus; Markus Bleich
Journal:  Genome Med       Date:  2022-09-09       Impact factor: 15.266

5.  Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer.

Authors:  Facai Zhang; Xiaoming Wang; Yunjin Bai; Huan Hu; Yubo Yang; Jiahao Wang; Yin Tang; Honggui Ma; Dechao Feng; Dengxiong Li; Ping Han
Journal:  Front Genet       Date:  2021-05-26       Impact factor: 4.599

6.  Development of cancer prognostic signature based on pan-cancer proteomics.

Authors:  Weiguo Huang; Jianhui Chen; Wanqing Weng; Yukai Xiang; Hongqi Shi; Yunfeng Shan
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.